Lantheus Holdings LNTH
Nasdaq · In Vitro & In Vivo Diagnostic Substances · $6.7BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $425.2M | $935.1M | $1.3B | $1.5B | $1.5B | +0.5% | +38.0% | |
| Cost of Revenue (COGS) | $237.5M | $353.4M | $586.9M | $545.6M | $599.7M | +9.9% | +26.1% | |
| Gross Profit | $187.7M | $581.7M | $709.5M | $988.3M | $942.0M | −4.7% | +49.7% | |
| Research & Development (R&D) | $45.0M | $311.7M | $77.7M | $168.1M | $177.3M | +5.5% | +40.9% | |
| Total Operating Expenses | $248.5M | $545.5M | $344.9M | $531.3M | $631.1M | +18.8% | +26.2% | |
| Operating Income (EBIT) | $-60.8M | $36.2M | $364.6M | $457.0M | $310.8M | −32.0% | — | |
| Interest Expense | $7.8M | $7.2M | $20.0M | $19.7M | $19.7M | +0.4% | +26.3% | |
| Income Tax Expense | $-3.8M | $-1.3M | $84.3M | $118.5M | $80.2M | −32.3% | — | |
| GAAP Net Income | $-71.3M | $28.1M | $326.7M | $312.4M | $233.6M | −25.2% | — | |
| Diluted EPS | $-1.06 | $0.40 | $4.65 | $4.36 | $3.41 | −21.8% | — | |
| Diluted Shares | 67.5M | 70.7M | 70.2M | 71.7M | 68.4M | −4.5% | +0.4% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $100.7M | $417.2M | $715.3M | $914.5M | $360.8M | −60.5% | +37.6% | |
| Inventory | $35.1M | $35.5M | $64.0M | $68.0M | $64.7M | −4.9% | +16.5% | |
| Total Current Assets | $235.8M | $677.6M | $1.1B | $1.3B | $900.0M | −32.2% | +39.8% | |
| Total Assets | $863.8M | $1.3B | $1.7B | $2.0B | $2.2B | +12.5% | +26.7% | |
| Total Current Liabilities | $90.5M | $247.7M | $187.3M | $240.5M | $333.4M | +38.6% | +38.5% | |
| Total Debt (Short + Long Term) | $186.4M | $558.4M | $558.9M | $559.0M | $558.8M | −0.0% | +31.6% | |
| Total Liabilities | $399.3M | $874.1M | $835.3M | $892.3M | $1.1B | +27.5% | +29.9% | |
| Stockholders' Equity | $464.4M | $447.1M | $815.9M | $1.1B | $1.1B | +0.2% | +23.8% | |
| Net Cash / (Net Debt) | $-85.8M | $-141.2M | $156.4M | $355.4M | $-198.0M | −155.7% | — | |
| Invested Capital | $550.2M | $588.3M | $659.5M | $732.6M | $1.3B | +75.8% | +23.7% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $53.9M | $281.8M | $305.3M | $544.8M | $390.1M | −28.4% | +64.0% | |
| Depreciation & Amortization (D&A) | — | — | — | — | $23.3M | — | — | |
| Stock-Based Compensation (SBC) | $15.9M | $29.3M | $50.5M | $76.4M | $85.6M | +12.0% | +52.2% | |
| Share Repurchases (Buybacks) | $0 | $75.0M | $0 | $100.0M | $300.0M | +200.0% | — | |
| Dividends Paid | — | — | — | — | $123,000 | — | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.